Filtered By:
Drug: Canagliflozin
Management: Food and Drug Administration (FDA)
This page shows you your search results in order of relevance.
Order by Relevance | Date
Total 2 results found since Jan 2013.
FDA Approves Invokana (canagliflozin) to Reduce the Risk of Heart Attack, Stroke or Cardiovascular Death in Adults with Type 2 Diabetes and Established Cardiovascular Disease
TITUSVILLE, NJ, October 30, 2018– The Janssen Pharmaceutical Companies of Johnson& Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved Invokana (canagliflozin) to reduce the risk of major adverse...
Source: Drugs.com - New Drug Approvals - October 30, 2018 Category: Drugs & Pharmacology Source Type: news
A Call for a New Paradigm for Diabetes Care in the Era of Sodium –Glucose Cotransporter 2 Inhibitors (SGLT2i)
This article is based on previously conducted studies and the authors disclose their roles in relevant trials in the Acknowledgements.
Source: Cardiology and Therapy - July 12, 2020 Category: Cardiology Source Type: research
